Limits...
TFPI-2 silencing increases tumour progression and promotes metalloproteinase 1 and 3 induction through tumour-stromal cell interactions.

Gaud G, Iochmann S, Guillon-Munos A, Brillet B, Petiot S, Seigneuret F, Touzé A, Heuzé-Vourc'h N, Courty Y, Lerondel S, Gruel Y, Reverdiau P - J. Cell. Mol. Med. (2011)

Bottom Line: Tissue factor pathway inhibitor-2 (TFPI-2) is a potent inhibitor of plasmin which activates matrix metalloproteinases (MMPs) involved in degradation of the extracellular matrix.Its secretion in the tumour microenvironment makes TFPI-2 a potential inhibitor of tumour invasion and metastasis.This study also reveals for the first time that pulmonary fibroblasts incubated with conditioned media from TFPI-2 silencing cancer cells exhibited increased expression of MMPs, particularly MMP-1, -3 and -7, that are likely involved in lung cancer cell invasion through the surrounding stromal tissue, thus enhancing formation of metastases.

View Article: PubMed Central - PubMed

Affiliation: Inserm, U618, Université François Rabelais, Tours, France.

Show MeSH

Related in: MedlinePlus

Effects of TFPI-2 down-regulation on metalloproteinase and EMMPRIN in non-small lung cancer cells. (A) MMP and EMMPRIN transcript levels were quantified using real-time RT-PCR in lung cancer cells stably transfected with miRNA-1b and -2b targeting TFPI-2 mRNA and in miRNA-Neg clone cells. The copy numbers of each transcript were normalized to 106 copies of β-actin. Results represent the mean ± S.E.M. from four independent mRNA extractions and real-time RT-PCR performed in triplicate. (*P < 0.05, compared with the miRNA-Neg clone; **P < 0.001; ***P < 0.0001, Student t-test). (B) Immunofluorescence staining of miRNA-1b, -2b and miRNA-Neg clones using monoclonal antibodies against MMP-1, -3 and -7 (original magnification, ×40).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3822788&req=5

fig05: Effects of TFPI-2 down-regulation on metalloproteinase and EMMPRIN in non-small lung cancer cells. (A) MMP and EMMPRIN transcript levels were quantified using real-time RT-PCR in lung cancer cells stably transfected with miRNA-1b and -2b targeting TFPI-2 mRNA and in miRNA-Neg clone cells. The copy numbers of each transcript were normalized to 106 copies of β-actin. Results represent the mean ± S.E.M. from four independent mRNA extractions and real-time RT-PCR performed in triplicate. (*P < 0.05, compared with the miRNA-Neg clone; **P < 0.001; ***P < 0.0001, Student t-test). (B) Immunofluorescence staining of miRNA-1b, -2b and miRNA-Neg clones using monoclonal antibodies against MMP-1, -3 and -7 (original magnification, ×40).

Mentions: Levels of MMP-1, -2, -3, -7, -9, -13, -14 and EMMPRIN transcripts were quantified in miRNA-Neg, miRNA-1b and -2b clones using RT and real-time PCR (Fig. 5A). Varying amounts of MMP transcripts were quantified in all cell clones, with fewer than 10 copies for MMP-9, -13 and -14 to more than 105 copies for MMP-1 and EMMPRIN. A 5.5-fold and an 8.6-fold increase in MMP-1 transcripts were found for miRNA-1b and -2b clones, respectively, when compared to miRNA-Neg cells (P < 0.001). Similar results were observed with MMP-3 since mRNA levels were significantly increased (P < 0.01) in miRNA-1b and -2b cell clones (11.3-fold and 10.4-fold, respectively) compared to the miRNA-Neg clone. Immunocytochemical staining also clearly showed that this increase in MMP-1 and -3 transcript levels was associated with enhanced protein expression (Fig. 5B). No significant differences were found in mRNA expression for MMP-9, -13, -14 and EMM-PRIN in either miRNA-1b or -2b compared to the control clone (Fig. 3A). In contrast, MMP-7 and MMP-2 transcript levels were significantly decreased in miRNA-1b (P < 0.01) and -2b (P < 0.001 and P < 0.01, respectively) clones. As shown in Fig. 5(B), MMP-7 protein expression was slightly decreased in both miRNA clones.


TFPI-2 silencing increases tumour progression and promotes metalloproteinase 1 and 3 induction through tumour-stromal cell interactions.

Gaud G, Iochmann S, Guillon-Munos A, Brillet B, Petiot S, Seigneuret F, Touzé A, Heuzé-Vourc'h N, Courty Y, Lerondel S, Gruel Y, Reverdiau P - J. Cell. Mol. Med. (2011)

Effects of TFPI-2 down-regulation on metalloproteinase and EMMPRIN in non-small lung cancer cells. (A) MMP and EMMPRIN transcript levels were quantified using real-time RT-PCR in lung cancer cells stably transfected with miRNA-1b and -2b targeting TFPI-2 mRNA and in miRNA-Neg clone cells. The copy numbers of each transcript were normalized to 106 copies of β-actin. Results represent the mean ± S.E.M. from four independent mRNA extractions and real-time RT-PCR performed in triplicate. (*P < 0.05, compared with the miRNA-Neg clone; **P < 0.001; ***P < 0.0001, Student t-test). (B) Immunofluorescence staining of miRNA-1b, -2b and miRNA-Neg clones using monoclonal antibodies against MMP-1, -3 and -7 (original magnification, ×40).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3822788&req=5

fig05: Effects of TFPI-2 down-regulation on metalloproteinase and EMMPRIN in non-small lung cancer cells. (A) MMP and EMMPRIN transcript levels were quantified using real-time RT-PCR in lung cancer cells stably transfected with miRNA-1b and -2b targeting TFPI-2 mRNA and in miRNA-Neg clone cells. The copy numbers of each transcript were normalized to 106 copies of β-actin. Results represent the mean ± S.E.M. from four independent mRNA extractions and real-time RT-PCR performed in triplicate. (*P < 0.05, compared with the miRNA-Neg clone; **P < 0.001; ***P < 0.0001, Student t-test). (B) Immunofluorescence staining of miRNA-1b, -2b and miRNA-Neg clones using monoclonal antibodies against MMP-1, -3 and -7 (original magnification, ×40).
Mentions: Levels of MMP-1, -2, -3, -7, -9, -13, -14 and EMMPRIN transcripts were quantified in miRNA-Neg, miRNA-1b and -2b clones using RT and real-time PCR (Fig. 5A). Varying amounts of MMP transcripts were quantified in all cell clones, with fewer than 10 copies for MMP-9, -13 and -14 to more than 105 copies for MMP-1 and EMMPRIN. A 5.5-fold and an 8.6-fold increase in MMP-1 transcripts were found for miRNA-1b and -2b clones, respectively, when compared to miRNA-Neg cells (P < 0.001). Similar results were observed with MMP-3 since mRNA levels were significantly increased (P < 0.01) in miRNA-1b and -2b cell clones (11.3-fold and 10.4-fold, respectively) compared to the miRNA-Neg clone. Immunocytochemical staining also clearly showed that this increase in MMP-1 and -3 transcript levels was associated with enhanced protein expression (Fig. 5B). No significant differences were found in mRNA expression for MMP-9, -13, -14 and EMM-PRIN in either miRNA-1b or -2b compared to the control clone (Fig. 3A). In contrast, MMP-7 and MMP-2 transcript levels were significantly decreased in miRNA-1b (P < 0.01) and -2b (P < 0.001 and P < 0.01, respectively) clones. As shown in Fig. 5(B), MMP-7 protein expression was slightly decreased in both miRNA clones.

Bottom Line: Tissue factor pathway inhibitor-2 (TFPI-2) is a potent inhibitor of plasmin which activates matrix metalloproteinases (MMPs) involved in degradation of the extracellular matrix.Its secretion in the tumour microenvironment makes TFPI-2 a potential inhibitor of tumour invasion and metastasis.This study also reveals for the first time that pulmonary fibroblasts incubated with conditioned media from TFPI-2 silencing cancer cells exhibited increased expression of MMPs, particularly MMP-1, -3 and -7, that are likely involved in lung cancer cell invasion through the surrounding stromal tissue, thus enhancing formation of metastases.

View Article: PubMed Central - PubMed

Affiliation: Inserm, U618, Université François Rabelais, Tours, France.

Show MeSH
Related in: MedlinePlus